Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.60 |
| ▸ | STS | P08842 | 11/20 | 0.60 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879844 | 0.87 | CYP19A1 (0.57) | CYP19A1STSCA2 | |
| SCHEMBL16879474 | 0.83 | CYP19A1 (0.63) | CYP19A1STSGRM2CA2 | |
| SCHEMBL16879469 | 0.81 | CYP19A1 (0.58) | CYP19A1STSGRM2CA2 | |
| SCHEMBL16879864 | 0.79 | CYP19A1 (0.56) | CYP19A1STSCA2 | |
| SCHEMBL16879644 | 0.79 | STS (0.47) | CYP19A1STSCA2 | |
| SCHEMBL16879876 | 0.78 | CYP19A1 (0.55) | CYP19A1STSCA2 | |
| SCHEMBL16879973 | 0.77 | CYP19A1 (0.60) | CYP19A1STSGRM2CA2 | |
| SCHEMBL306829 | 0.75 | CYP19A1 (1.00) | CYP19A1STSCA2 | |
| SCHEMBL16879886 | 0.75 | CYP19A1 (0.60) | CYP19A1STSCA2 | |
| SCHEMBL16879473 | 0.73 | GRM2 (0.55) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089966-B1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | ESTRYX PHARMA LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-9682941-B2 | Substituted biphenyl analogues as dual inhibitors of aromatase and sulfatase | ESTRYX PHARMA LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | BEAUFOUR IPSEN TIANJIN PHARMACEUTICAL CO., LTD (CN) | 2017-01-05 | — | — | US | disclosed |
| EP-3089966-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | Beaufour Ipsen Tianjin Pharmaceutical Co., Ltd (CN) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015100609-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | BEAUFOUR IPSEN TIANJIN PHARMACEUTICAL CO., LTD (CN) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | CYP19A1, SULT2A1, STS | CYP19A1 1/4885STS 3/4885GRM2 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.